The EMA grants orphan drug designation for Sucampo Pharmaceuticals' (SCMP) retinitis pigmentosa...

|About: Sucampo Pharmaceuticals, Inc. (SCMP)|By:, SA News Editor

The EMA grants orphan drug designation for Sucampo Pharmaceuticals' (SCMP) retinitis pigmentosa treatment unoprostone isopropyl. The FDA has already given the product the same designation and an alternate formulation is FDA approved. (PR)